The research, drawn from the Japan Comprehensive Process for End-of-Life Care and Organ Donation after Brain Death, or J-RESPECT, cohort, analyzed 204 brain-dead organ donors across 16 tertiary emergency and critical care centers between July 2010 and December 2023. These cases represented 21.8 percent of all brain-dead organ donations nationwide during the study period, making the dataset an unusually comprehensive window into real-world Japanese donor management. The findings were published in the journal Neurocritical Care by a team led by Tetsuya Yumoto of Okayama University, together with the J-RESPECT study group.

The physiological challenge that the study addresses is formidable. Brain death unleashes a cascade of devastating disturbances throughout the body: autonomic storm, hemodynamic collapse, hormonal deficiencies, and systemic inflammation. The loss of hypothalamic and pituitary function frequently triggers diabetes insipidus, in which the kidneys excrete enormous volumes of dilute urine, destabilizing blood pressure and fluid balance. A Korean nationwide study cited by the authors reported that cardiac arrest strikes 22.2 percent of donors during the brain death determination process itself. Every episode of cardiovascular instability threatens the viability of organs that might otherwise save lives downstream.

To combat this storm, intensivists around the world routinely deploy hormone replacement therapy, most commonly vasopressin to control diabetes insipidus and support blood pressure, and corticosteroids to stabilize hemodynamics and blunt the inflammatory response. Yet the evidence base for both practices has been surprisingly thin. A previous meta-analysis concluded that existing clinical evidence was insufficient to confirm or refute whether corticosteroids improve donor or recipient outcomes, and observational studies of vasopressin have generally evaluated the drug in isolation rather than alongside the other therapies donors typically receive.

The Japanese team set out to disentangle these overlapping treatments. Donors were classified into a high-yield group of six or more procured organs and a low-yield group of five or fewer, based on the cohort median of six organs. Lungs and kidneys were each counted as two organs when both sides were procured, while a liver counted as one even if split among multiple recipients. The researchers then applied generalized estimating equations, a statistical framework that accounts for the fact that donor management practices cluster within institutions, adjusting for age, sex, out-of-hospital cardiac arrest, admission Sequential Organ Failure Assessment score, catecholamine use, time from admission to procurement, and, critically, the number of organs the family had requested.

The results were unambiguous on one point and surprising on another. Low-dose methylprednisolone, defined as less than 15 milligrams per kilogram per day in methylprednisolone equivalents, was associated with nearly triple the odds of high-yield organ procurement compared with no corticosteroid use, with an adjusted odds ratio of 2.86 and a 95 percent confidence interval of 1.45 to 5.63. High-dose methylprednisolone at or above 15 milligrams per kilogram per day showed no such association. Vasopressin dose, categorized across four exposure levels, was not independently associated with overall organ yield after adjustment. The number of organs requested by the donor’s family was also independently linked to high-yield procurement, underscoring how consent conversations shape the eventual harvest.

In exploratory organ-specific analyses, the picture became even more nuanced. High-dose methylprednisolone was associated with dramatically higher odds of left lung donation, with an odds ratio of 8.99, while moderate-dose vasopressin was associated with lower odds of right lung donation. No consistent associations emerged for the heart, liver, or pancreas, and kidney models were not fitted because donation was nearly universal. The authors emphasize that these organ-specific findings are hypothesis-generating, particularly given the multiple comparisons performed, but they note that the lung signal is biologically plausible: corticosteroids may attenuate the inflammatory lung injury that accompanies brain death, a mechanism supported by earlier experimental and clinical work.

The study’s sensitivity analyses strengthened the central conclusion. When the yield threshold was shifted to five versus four organs, low-dose methylprednisolone remained significantly associated with the outcome, and when organ count was treated as a continuous variable, low-dose methylprednisolone was independently associated with an additional 0.46 organs procured per donor. Adjusting for the study period and replacing the admission-to-procurement interval with the brain-death-determination-to-procurement interval produced similar results. Vasopressin, by contrast, never emerged as an independent predictor of yield, suggesting that its principal benefit may lie in preserving donor physiology, controlling diabetes insipidus, and reducing catecholamine requirements rather than directly increasing the number of organs recovered.

The Japanese context adds an important dimension to the findings. The median time from hospital admission to organ procurement was 10 days, far longer than is typical in Western countries, reflecting Japan’s legally mandated process of two independent brain death determinations performed at least six hours apart, along with detailed family consent specifying which organs may be donated. During most of the study period, patients on extracorporeal membrane oxygenation could not be legally declared brain-dead under Japanese guidelines, a restriction lifted only on January 1, 2024. The scarcity of donation is itself striking: of 906 designated institutions, only 297 had ever performed a brain-dead donation procedure as of 2023, averaging roughly three cases per institution over twelve years.

The authors are careful to frame their conclusions cautiously. The study lacked recipient graft survival data, could not capture the reasons organs were not procured, and included only donors from whom at least one organ was ultimately recovered. Illness severity was adjusted only through the admission SOFA score, and variables such as target blood pressure, fluid balance, and infections were not available. Because the organ-specific analyses were exploratory and unadjusted for multiple comparisons, they require confirmation in prospective studies. Nevertheless, the message for the transplant community is clear and potentially consequential: when it comes to maximizing the gift that a brain-dead donor can give, the dose of corticosteroid may matter more than the drugs have been given credit for, and the humble low-dose regimen, rather than aggressive high-dose protocols or vasopressin titration, may be the key to unlocking more organs from every act of extraordinary generosity.

Subject of Research: Associations of vasopressin and corticosteroid therapy with organ yield in brain-dead organ donors

Article Title: Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan

Article References: Yumoto, T., Naito, H., Hongo, T., Obara, T., Nojima, T., Tsukahara, K., Hayakawa, M., Yokobori, S., Nishiyama, K., Atsumi, T., Tasaki, O., Yamamura, Y., Yorifuji, T., Nakao, A., and J-RESPECT study group, Tsurukiri, J., Hayamizu, M., Murahashi, S., Hayashi, M., … Hosotani, M. (2026). Associations of Vasopressin and Corticosteroid Therapy with Organ Yield in Brain-Dead Donors: A Multicenter Cohort Study in Japan. Neurocritical Care. https://doi.org/10.1007/s12028-026-02645-6

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02645-6

Keywords: brain death, organ donation, organ transplantation, vasopressin, methylprednisolone, corticosteroids, hormone replacement therapy, donor management, critical care, J-RESPECT, organ yield, Japan

DCUs are specialized units designed to optimize the care of deceased donors, facilitating organ preservation, assessment, and eventual procurement. These units have garnered support for their ability to standardize donor management and improve transplantation success rates. However, this study reveals a heterogeneous adoption pattern across donation service areas (DSAs), unevenly distributing access to DCUs and thereby potentially compromising equitable organ donation opportunities. The uneven distribution means that a significant number of donors are located over a 180-minute drive from the nearest DCU, underscoring a critical geographic barrier.

The findings raise pressing concerns about the systemic boundaries currently defining organ procurement organizations (OPOs) and their operational reach. Donation service areas, which are typically delineated by regulatory and administrative borders, may unintentionally hamper the efficient placement and transfer of donors to the closest and most adequately equipped care units. This siloed approach may delay critical donor management interventions, reducing the viability of organs and diminishing overall transplantation outcomes.

Transportation logistics emerge as a critical focal point in this context. The study suggests that overcoming service area boundaries through innovative donor transport solutions could mitigate the current inefficiencies. By enabling cross-boundary transfer of donors to DCUs, healthcare systems might reduce time delays and enhance organ preservation quality. This approach would require coordination among regional OPOs, as well as investment in transport infrastructure and clinical protocols tailored for rapid donor movement.

Another solution proposed involves expanding the number of DCUs within acute care hospitals, thus reducing geographic gaps and shortening the time required for donor admission to specialized care. Integration of DCUs into existing hospital infrastructures presents challenges in resource allocation, staffing, and training but could yield significant gains in donor management quality and organ yield. The study calls for targeted policy initiatives and funding streams to incentivize such expansions, especially in underserved and rural areas.

Beyond logistical considerations, the study’s implications extend to ethical and clinical practices within transplant medicine. Ensuring equitable access to DCUs aligns with broader goals of fairness and maximizing life-saving opportunities through organ transplantation. Uneven DCU access risks perpetuating disparities among populations geographically distant from these units, potentially reflecting socioeconomic and demographic inequities. Addressing these gaps is therefore not only a clinical imperative but a public health and social justice concern.

Technological advances in remote donor monitoring and telemedicine integration may support overcoming geographic limitations, supplementing physical DCU presence by enabling expert consultation and real-time management guidance. These tools could facilitate earlier detection of donor instability and optimize protocols prior to transport or in smaller hospitals lacking dedicated DCUs. Incorporating such innovations may constitute another layer of intervention to complement infrastructural reforms.

The study’s rigorous cohort design strengthens the validity of its conclusions, drawing on comprehensive data sets that track donor locations, transport times, and DCU availability across multiple OPOs. This methodology allows for sophisticated spatial and temporal analyses, elucidating patterns that inform practical recommendations. The authors advocate for a system-level realignment to harness efficiencies, reduce organ loss, and ultimately save more recipient lives.

Regulatory reform may be a pivotal driver of change, aligning incentives for cross-boundary cooperation among OPOs and mandating minimum standards for DCU access. This could involve revising allocation policies, reimbursement models, and accountability frameworks to foster collaboration across traditional geographic lines. The study highlights that entrenched boundaries, while administratively convenient, may pose unnecessary barriers to the fluid management of donor resources.

In sum, this investigation provides a comprehensive appraisal of the structural and logistical challenges impacting donor care units and their role in deceased donor management. By recommending both the expansion of DCUs into acute care settings and innovative donor transport strategies that transcend donation service area boundaries, the study charts a forward path to enhance organ donation efficiency. Adoption of these measures would necessitate multifaceted collaboration among clinical providers, OPOs, policymakers, and health system leaders.

As the field continues to evolve toward optimizing organ transplantation outcomes, this study underscores the critical importance of addressing geography, infrastructure, and policy simultaneously. In doing so, it contributes a vital evidence base for engineering a more equitable, effective, and responsive organ donation system capable of meeting current and future demands.

Corresponding Author: Dr. Peter P. Reese can be contacted at peter.reese@vumc.org for further inquiries regarding the study findings and implications.

Subject of Research: Organ donation infrastructure and donor care unit accessibility

Article Title: [Not provided in the source]

News Publication Date: [Not provided in the source]

Web References: doi:10.1001/jamanetworkopen.2026.1703

Keywords: Organ donation, donor care units, brain death, donation service areas, deceased donors, transplant logistics, acute care hospitals, donor transport, health care system efficiency, geographical disparities, organ procurement organizations

In recent years, organ shortages have reached epidemic levels, resulting in an urgent need for systemic reforms in how organs are procured. The study highlights the necessity of dedicated full-time organ recovery teams as a key to addressing this crisis. These specialized units are equipped to streamline the organ recovery process, ensuring that the needs of both donors and recipients are met with precision and care. The researchers advocate that by harnessing the full potential of OPOs and transplant centers through dedicated teams, the overall efficiency of organ procurement can be greatly enhanced.

One of the major findings of the study is the stark contrast between full-time dedicated recovery teams and traditional, part-time efforts. The researchers delve into the better coordination, training, and focus that full-time teams can provide, setting a new standard in the organ recovery landscape. Traditional approaches often suffer from inconsistent practices and lack of urgency, whereas dedicated teams operate with a singular mission: to optimize the organ recovery process and improve transplant rates. This dedicated focus translates into tangible results, indicating a future where fewer patients have to wait for life-saving procedures.

Furthermore, the involvement of private sector teams in organ recovery opens up new avenues for collaboration and innovation. The inclusion of these entities introduces diverse perspectives and resources, which can lead to more comprehensive strategies for organ procurement. The study presents case examples where collaborations between public and private sectors have yielded impressive increases in organ donation rates. Such partnerships could potentially address the organ scarcity issue from multiple angles, creating a multifaceted approach to saving lives.

The study also emphasizes the importance of continual training and skill enhancement for recovery team personnel. As medical technology and procedures evolve, so too must the knowledge and capabilities of those involved in organ recovery. The researchers argue that continuous professional development leads to better outcomes, both for organ recovery and for the subsequent success of transplantation procedures. This focus on education and skills training can help foster a culture of excellence within organ recovery teams, enabling them to adapt to challenges and innovate in their practices.

Additionally, the emotional and psychological aspects of organ recovery cannot be overlooked. The study outlines the critical need for sensitivity towards donor families and recipients, advocating that dedicated recovery teams must not only be skilled technicians but also compassionate communicators. Building rapport with grieving families can increase the likelihood of donation, while also ensuring that the dignity of the donor is preserved. It is vital that teams approach organ recovery with empathy, understanding that every organ recovered represents a life lost and a future salvaged.

The data gathered for the study reinforces the notion that effectiveness in organ recovery translates directly into lives saved. Through statistical analysis, the authors illustrate the positive correlation between the presence of dedicated teams and increased organ donation outcomes. This data serves as a compelling argument for healthcare systems to invest in the establishment and maintenance of full-time organ recovery teams across different sectors. Enhanced outcomes can not only improve patient care but also bolster public confidence in transplantation as a viable lifesaving option.

Public awareness and education around organ donation also emerge as pivotal themes throughout the study. The authors suggest that with stronger campaigns to normalize organ donation, more families may choose to donate their loved ones’ organs in times of grief. These educational efforts, coupled with improved recovery systems, could serve to alleviate the dire circumstances many face while awaiting transplants. The more knowledge communities have about the impact of organ donation and the processes involved, the more likely they are to engage in this life-affirming act.

Equally significant are the technological advancements that aid recovery efforts. Among the innovative approaches discussed in the paper are new organ preservation techniques and improved logistical systems for organ transport. These technological improvements should be leveraged alongside dedicated recovery teams for optimal efficiency. Technology can help monitor the viability of donated organs more accurately, allowing for better decision-making throughout the recovery and transplantation process.

The collaboration among organ procurement organizations, transplant centers, and private sector teams carries the potential for regional and national models of excellence in organ recovery. By sharing best practices and learning from each other’s successes and setbacks, these entities can create a cohesive framework for organ recovery that is both adaptable and resilient. Such collaboration not only increases organ donation rates but also enhances the overall quality of transplantation services offered to patients across different regions.

As the research advances, the urgency for policy changes becomes clear. Advocating for more support and funding for dedicated organ recovery teams is essential. Policymakers need to recognize the life-saving potential these teams possess and support legislative measures that enhance funding and resources for organ procurement. A supportive policy framework would provide these teams with the tools they require to operate at peak effectiveness, ultimately benefiting countless patients in dire need of transplants.

In conclusion, the study on dedicated full-time organ recovery teams presents invaluable insights into the future of organ transplantation. The necessity for focused teams, the involvement of diverse sectors, the importance of ongoing training, and the emotional aspects of donation all weave together to form a comprehensive narrative about the dynamics of organ recovery. As global health systems grapple with the challenges of increasing organ donations, these findings stand as a clarion call for a re-evaluation of current practices—one that places dedicated recovery teams at the forefront of organ procurement efforts and, ultimately, saves lives.

By embracing the findings of this study, healthcare systems can usher in a new era of transplantation that respects the complexity and urgency of organ recovery. The implications of this research extend far beyond numbers; they embody the hope of renewed life for thousands of patients grappling with chronic illnesses. In a world where the power of medical technology is boundless, having dedicated individuals working full-time to save lives through organ recovery becomes an indispensable part of the solution.

Subject of Research: Dedicated Full Time Organ Recovery Teams

Article Title: Dedicated Full Time Organ Recovery Teams from Organ Procurement Organizations, Transplant Centers, and the Private Sector

Article References:

Lee, G.R., Punjala, S.R., Washburn, W.K. et al. Dedicated Full Time Organ Recovery Teams from Organ Procurement Organizations, Transplant Centers, and the Private Sector.
Curr Transpl Rep 12, 16 (2025). https://doi.org/10.1007/s40472-025-00473-9

Image Credits: AI Generated

DOI:

Keywords: Organ recovery, transplantation, dedicated teams, organ procurement, healthcare policy.